{"id":11220,"date":"2020-09-17T00:00:00","date_gmt":"2020-09-17T05:00:00","guid":{"rendered":"https:\/\/myeloma.ca\/1970\/01\/01\/la-pomalidomide-le-bortezomib-et-la-dexamethasone-pour-traiter-les-patients-atteints-dun-myelome-multiple-precedemment-traites-avec-du-lenalidomide-optimismm\/"},"modified":"2025-08-19T08:28:19","modified_gmt":"2025-08-19T13:28:19","slug":"la-pomalidomide-le-bortezomib-et-la-dexamethasone-pour-traiter-les-patients-atteints-dun-myelome-multiple-precedemment-traites-avec-du-lenalidomide-optimismm","status":"publish","type":"post","link":"https:\/\/myeloma.ca\/fr\/2020\/09\/17\/la-pomalidomide-le-bortezomib-et-la-dexamethasone-pour-traiter-les-patients-atteints-dun-myelome-multiple-precedemment-traites-avec-du-lenalidomide-optimismm\/","title":{"rendered":"LA POMALIDOMIDE, LE BORT\u00c9ZOMIB ET LA DEXAM\u00c9THASONE POUR TRAITER LES PATIENTS ATTEINTS D\u2019UN MY\u00c9LOME MULTIPLE PR\u00c9C\u00c9DEMMENT TRAIT\u00c9S AVEC DU L\u00c9NALIDOMIDE (OPTIMISMM)"},"content":{"rendered":"

Dans l\u2019essai de phase 3 OPTIMISMM, la pomalidomide, le bort\u00e9zomib et la dexam\u00e9thasone (PVd) ont d\u00e9montr\u00e9 une efficacit\u00e9 sup\u00e9rieure \u00e0 celle du bort\u00e9zomib et de la dexam\u00e9thasone (Vd) chez les patients atteints d\u2019un my\u00e9lome multiple r\u00e9cidivant ou r\u00e9fractaire ayant re\u00e7u un traitement ant\u00e9rieur de l\u00e9nalidomide, y compris les cas r\u00e9fractaires au l\u00e9nalidomide. Cette analyse a \u00e9valu\u00e9 les r\u00e9sultats chez les patients lors de la premi\u00e8re r\u00e9cidive (N = 226) en fonction du statut au l\u00e9nalidomide, de l\u2019exposition ant\u00e9rieure au bort\u00e9zomib et d\u2019une greffe ant\u00e9rieure de cellules souches.<\/p>\n

Consultez les d\u00e9tails de l\u2019\u00e9tude, ici<\/strong><\/a> (en anglais).<\/p>\n","protected":false},"excerpt":{"rendered":"

Dans l\u2019essai de phase 3 OPTIMISMM, la pomalidomide, le bort\u00e9zomib et la dexam\u00e9thasone (PVd) ont d\u00e9montr\u00e9 une efficacit\u00e9 sup\u00e9rieure \u00e0 celle du bort\u00e9zomib et de la dexam\u00e9thasone (Vd) chez les patients atteints d\u2019un my\u00e9lome multiple r\u00e9cidivant ou r\u00e9fractaire ayant re\u00e7u un traitement ant\u00e9rieur de l\u00e9nalidomide, y compris les cas r\u00e9fractaires au l\u00e9nalidomide. Cette analyse a […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[53,50,58,52],"tags":[],"class_list":["post-11220","post","type-post","status-publish","format-standard","hentry","category-actualites-et-evenement","category-news-events","category-nouvelles-de-myelome-canada","category-whats-new-at-myeloma-canada"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11220","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/comments?post=11220"}],"version-history":[{"count":1,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11220\/revisions"}],"predecessor-version":[{"id":31312,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11220\/revisions\/31312"}],"wp:attachment":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/media?parent=11220"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/categories?post=11220"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/tags?post=11220"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}